This Fund Dumped a $16 Million Waystar Stake as Shares Lagged the Market by Nearly 30 Points

New Mexico-based Westwind Capital fully liquidated its 420,897-share position in Waystar (estimated $15.96M), reducing its stake to zero at quarter-end after that holding represented 3.3% of prior-quarter AUM. Waystar trades at $33.08 with a $6 billion market cap and TTM revenue of $1.04 billion and net income of $111.18 million; recent results showed Q3 revenue of $268.7 million (+12% YoY), a 42% adjusted EBITDA margin, 113% net revenue retention, and $82 million in operating cash flow, with management raising full-year guidance. The exit appears portfolio-driven as Westwind pivots into mega-cap compounders (Visa, Mastercard, Alphabet, Amazon, Intuitive Surgical), reflecting a preference for liquidity and durability despite Waystar's solid fundamentals and recent underperformance versus the S&P 500.

Analysis

Market structure: Westwind’s $15.96m sale (420,897 shares) is meaningful for its portfolio (3.3% prior AUM) but immaterial to Waystar’s $6bn market cap (~0.27%). Short-term losers: Waystar (WAY) holders risk sentiment-driven selling and higher implied volatility; winners are large-cap liquid compounders (V, MA, GOOGL, AMZN, ISRG) that attract reallocation flows and reduce portfolio tracking error. The real signal is allocation preference for liquidity and low idiosyncratic risk, not a fundamental indictment of Waystar’s 12% revenue growth and 113% NRR.

Risk assessment: Tail risks include failed integration of recent acquisitions, data/privacy regulation in healthcare payments, and a macro shock reducing elective procedures (20–30% revenue sensitivity scenario). Time horizons: immediate (days–weeks) expect 5–15% sentiment-driven moves; short-term (quarters) earnings/guidance will re-price multiples; long-term (2–5 years) fundamentals (adj. EBITDA margin ~42%, positive operating cashflow) determine value. Hidden dependencies: transaction-fee revenue scales with healthcare volumes and payer reimbursement rules; catalyst set = next quarterly guide, M&A updates, and regulatory notices.

Trade implications: Direct trade: selective long WAY with downside protection (puts or collars) to capture 30–40% upside if growth holds; alternatives are tactical call spreads ahead of a clean earnings print. Relative value: rotate 3–5% from small-cap healthcare SaaS into V/MA/GOOGL to capture liquidity premium and lower volatility. Cross-asset: minor credit spread widening for levered names; monitor WAY bond or credit metrics if available.

Contrarian angles: Consensus treats this as a thesis break — it’s more a liquidity trade; current ~12% 1-year decline vs S&P underperformance (~30ppt) likely overstates fundamental deterioration. If Waystar sustains NRR>110% and operating cashflow >$200m TTM, downside is limited and buying on 10–20% pullbacks could be mispriced. Historical parallel: profitable SaaS names with acquisition noise (e.g., ANET/old transitions) recovered once cashflow proof points returned within 2–4 quarters, suggesting a patient 12–18 month window.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Waystar (WAY) on weakness with a 12–18 month horizon; hedge with a 3–6 month put ~10% OTM (e.g., $30 strike) or create a costless collar by selling a 25% OTM call; set take-profit at $45 (+35%) and hard stop at $25 (−25%).
• If WAY declines >15% within 30 days or after earnings miss, scale to 5% using staggered tranches (25% increments) and buy a 9–12 month 30/50 call spread to limit premium risk while retaining 50–100% upside exposure.
• Overweight mega-cap compounders: shift 3–5% from small-cap healthcare SaaS into Visa (V) and Mastercard (MA) — allocate +2% to V and +2% to MA versus benchmark for 6–18 months; write 4–8 week covered calls ~4–6% OTM to harvest premium while holding conviction.
• Monitor three triggers before adding to WAY: (1) quarterly revenue beat + maintained guidance; (2) OCF >$250m annualized or sequential improvement +10% QoQ; (3) no major regulatory action within 90 days. If all three occur, increase position to 5–7%.